Phase II Study of GEN-001 in Combination with Avelumab in Patients with PD-L1–positive Locally Advanced, or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC) Who Have Progressed after Second-Line (2L) and Beyond (GEN001-201 Study).